Targeted Oncology Staff

During a Case-Based Roundtable® event, Pinkal Desai, MD, MPH, discusses the presentation of blastic plasmacytoid dendritic cell neoplasm vs other diseases in a patient case.

During a Case-Based Roundtable® event, Tiffany A. Traina, MD, surveyed participants on treatment for a patient who had progressed following endocrine therapy for metastatic breast cancer in the first article of a 2-part series.

During a live Community Case Forum event in partnership with the Minnesota Society of Clinical Oncology, Roberto A. Leon-Ferre, MD, discussed drugs targeting PIK3CA alterations in patients with ER+ metastatic breast cancer.

In separate, live virtual events, Michael J. Birrer, MD, PhD, and Jubilee Brown, MD, surveyed participants on the treatment of a postmenopausal woman with stage IVA endometrial cancer after first-line chemotherapy.

During a Case-Based Roundtable® event, Igor Makhlin, MD, discussed with participants their impressions of datopotamab deruxtecan as therapy for patients with HR-positive, HER2-negative breast cancer, and the sequential use of multiple antibody-drug conjugates.

During a Case-Based Roundtable® event, Jack Khouri, MD, and participants discussed the use of selinexor with dose modifications to manage toxicity in patients with relapsed/refractory multiple myeloma.

During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.

During a Case-Based Roundtable® event, Timothy Schmidt, MD, and participants discussed treatment selection for a 54-year-old patient with transplant eligible R-ISS stage 2/R2-ISS stage 3 IgG-κ myeloma.

During a Case-Based Roundtable® event, Andrew Yee, MD, discussed the use of carfilzomib-based regimens compared with other options for patients with multiple myeloma, including those refractory to lenalidomide in the first article of a 2-part series.

During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.

During a Case-Based Roundtable® event, Michael A. Postow, MD, discussed an indirect treatment comparison of nivolumab plus relatlimab vs nivolumab plus ipilimumab in patients with advanced melanoma in the second article of a 2-part series.

Ajaz M. Khan, MD, MBA, CPE, provides his insights into the novel biomarkers and up-front immunotherapies that are changing the landscape of treatment for patients with lung cancer.

During a Case-Based Roundtable® event, Adam D. Cohen, MD, discussed triplet vs quadruplet options for a patient with transplant eligible multiple myeloma and NCCN recommendations in the first article of a 2-part series.

In a live virtual event, Aditya Bardia, MD, MPH, discussed the treatment landscape for patients with advanced invasive breast cancer.

During a Case-Based Roundtable® event, John V. Heymach, MD, PhD, discusses the use of immunotherapy combinations based on patients PD-L1 expression in the first article of a 2-part series.

During a Case-Based Roundtable® event, Kristen Pettit, MD, discussed the use of pacritinib and momelotinib in cytopenic myelofibrosis in the second article of a 2-part series.

During a Case-Based Roundtable® event, Amer Zeidan, MBBS, reviewed data for luspatercept-aamt for patients with low-risk myelodysplastic syndrome in the second article of a 2-part series.

During a Case-Based Roundtable® event, Rana McKay, MD, discussed the updated favorable-risk group data for 4 frontline combination trials in renal cell carcinoma in the first article of a 2-part series.

During a Case-Based Roundtable® event, Joanna M. Rhodes, MD, MSCE, discussed issues related to toxicity and dose modification in treating patients with Hodgkin lymphoma.

During a Case-Based Roundtable® event, Surbhi Sidana, MD, discussed the KarMMa-3 trial of earlier-line CAR T-cell therapy in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series.

During a Case-Based Roundtable® event, Lori J. Wirth, MD, discussed with participants how they approach use of lenvatinib and other therapy for patients with radioactive iodine–refractory differentiated thyroid cancer.

During a Case-Based Roundtable® event, Amer Zeidan, MBBS, discussed how he would have approached a patient with anemia from low-risk myelodysplastic syndrome before the development of newer drugs in the first article of a 2-part series.

During a Case-Based Roundtable® event, Deepak Kilari, MD, discussed with participants how updated data on frontline regimens affects their choice of therapy for patients with metastatic clear cell renal cell carcinoma.

During a Case-Based Roundtable® event, Nizar M. Tannir, MD, discussed the importance of site of metastasis and other factors in the use of nivolumab plus ipilimumab in renal cell carcinoma in the first article of a 2-part series.

At a live virtual event, Moshe Ornstein, MD, looked at the latest data behind the 4 main combination therapies available for patients with metastatic renal cell carcinoma (RCC).

During a Case-Based Roundtable® event, Jack Khouri, MD, looked at selinexor trial data for a patient with relapsed/refractory multiple myeloma in the first article of a 2-part series.

During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, discussed with participants how they select treatment for a patient with ALK+ non–small cell lung cancer and brain metastases in the first article of a 2-part series.

During a Case-Based Roundtable® event, Timothy J. Pluard, MD, explores datopotamab deruxtecan as an option in hormone receptor–positive, HER2-negative breast cancer in the second article of a 2-part series.

During a Case-Based Roundtable® event, Michael A. Postow, MD, reviewed the use of nivolumab plus relatlimab for patients with advanced melanoma in the first article of a 2-part series.

During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed biomarker testing and treatment exposure for a patient with metastatic breast cancer in the second article of a 2-part series.